Cargando…
A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?
Objective: Pancreatic cancer is the most aggressive common cancer and is desperately in need of novel therapies. Unlike many other common cancers, there have been no new paradigm-changing therapies in the past 40 years beyond multi-agent chemotherapy. In this study, we perform the first comprehensiv...
Autores principales: | Katayama, Erryk S., Hue, Jonathan J., Bajor, David L., Ocuin, Lee M., Ammori, John B., Hardacre, Jeffrey M., Winter, Jordan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517959/ https://www.ncbi.nlm.nih.gov/pubmed/33014285 http://dx.doi.org/10.18632/oncotarget.27727 |
Ejemplares similares
-
The Impact of COVID-19 on Time-to-treatment in Pancreatic Adenocarcinoma: A Single Institutional Experience
por: Sugumar, Kavin, et al.
Publicado: (2021) -
The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis
por: Sugumar, Kavin, et al.
Publicado: (2021) -
Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer
por: Hue, Jonathan J., et al.
Publicado: (2021) -
Immunoadjuvant therapy in sepsis: novel strategies for immunosuppressive sepsis coming down the pike
por: Watanabe, Eizo, et al.
Publicado: (2018) -
The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs)
por: Mohamed, Amr, et al.
Publicado: (2022)